ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

ClinicalTrials.gov ID: NCT03819049

Public ClinicalTrials.gov record NCT03819049. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

Study identification

NCT ID
NCT03819049
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
836 participants

Conditions and interventions

Interventions

  • ExPEC10V Biological
  • ExPEC4V Biological
  • Placebo Biological
  • Prevnar 13 Biological

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 5, 2019
Primary completion
Jun 7, 2021
Completion
Dec 17, 2024
Last update posted
May 10, 2026

2019 – 2024

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Optimal Research Huntsville Alabama 35802
Optimal Research Melbourne Florida 32934
Qps-Mra, Llc Miami Florida 33143
Optimal Research Peoria Illinois 61614
Synexus Clinical Research US Inc Evansville Indiana 47714
Johnson County Clin-Trials Lenexa Kansas 66219
Synexus Clinical Research US Inc Richfield Minnesota 55432
Synexus Clinical Research US Inc Manhattan New York 10017
Rochester Clinical Research, Inc Rochester New York 14609
Synexus Clinical Research US Inc Akron Ohio 44311
Synexus Clinical Research US Inc Columbus Ohio 43212
Coastal Carolina Research Center North Charleston South Carolina 29405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03819049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03819049 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →